A cost-utility model estimated higher costs and fewer quality-adjusted life years from long-term benzodiazepine prescribing. Its outputs were model projections, not measured losses for an individual patient.
The study used Markov models for hypothetical sixty-five-year-olds over thirty-five annual cycles. Published probabilities, costs, and utilities represented selected adverse effects and alternative prescribing strategies.
The benzodiazepine model compared continued exposure with no sedative medication. Probabilistic sensitivity analysis described uncertainty within the modeled framework.
The model used class-level estimates, assumed ongoing exposure, and treated prescribing reductions as sustained. It did not include every interaction, underlying-disease effect, or within-class difference. Actual patients may stop, restart, switch, or use medication intermittently.
Economic inputs reflected a particular currency year and health-system perspective. The modeled willingness-to-pay threshold does not establish a current price or legal measure of damages.
This paper can explain a population-level economic argument for medication review. It cannot calculate a specific person’s lost lifespan, prove an adverse event occurred, or determine compensation from the average projected cost. Distinguish observed evidence feeding the model from the model’s own assumptions and estimates.
Original analysis of the supplied journal article, identified as PMC6359741.